Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system

Kidney International

Volumn 77, Issue 9, 2010, Pages 820-829

  Yu, Feng ^a,b,c   Wu, Li Hua ^d   Tan, Ying ^a,b,c   Li, Li Hua ^e   Wang, Cai Li ^f   Wang, Wen Ke ^g   Qu, Zhen ^a,b,c   Chen, Meng Hua ^d   Gao, Jun Jie ^e   Li, Zeng Yan ^f   Zheng, Xin ^a,b,c   Ao, Jie ^a,b,c   Zhu, Sai Nan ^a   Wang, Su Xia ^a,b,c   Zhao, Ming Hui ^a,b,c   Zou, Wan Zhong ^a,b,c   Liu, Gang ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d NINGXIA MEDICAL UNIVERSITY   (China)

^e CANGZHOU CENTRAL HOSPITAL   (China)

^f BAOTOU MEDICAL COLLEGE   (China)

^g Chifeng Second People's Hospital   (China)

Author keywords

Classification; Lupus nephritis; Tubulointerstitial lesions

Indexed keywords

ADULT; ARTICLE; CELL INFILTRATION; CHINA; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATORY CELL; INTERSTITIAL NEPHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; TUBULAR DYSFUNCTION;

EID: 77951092755     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.13     Document Type: Article

References (53)

1. Appel GB, Radhakrishnan J, D'Agati V. Secondary glomerular disease. In: Brenner BM (ed). Brenner & Rector's The Kidney, 8th edn. Philadephia: W.B. Saunders, 2008, pp 1067-1146.
2. D'Agati V. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren's syndrome, and rheumatoid arthritis. In: Jennette JC, Olson JL, Schwartz MM et al. (eds). Heptinstall's Pathology of the Kidney, 6th edn. Lippincott-Raven: Philadephia, 2007, pp 517-612.
3. McCluskey R. Lupus Nephritis. Appleton-Centery-Crofts: East Norwalk, CT, 1975.
4. Churg J, Sobin L. Renal Disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin: Tokyo, 1982.
5. Churg J, Bernstein J, Classock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin: Tokyo, 1995.
6. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
7. Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the 'Euro-Lupus Project'. Autoimmun Rev 2006; 5: 180-186. (Pubitemid 43234182)
8. Cervera R, Font J, Shoenfeld Y, European Working Party on Systemic Lupus Erythematosus. European Working Party on Systemic Lupus Erythematosus: A 15-year Report. Autoimmun Rev 2006; 5: 549-553.
9. Austin III HA, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
10. O'Dell JR, Hays RC, Guggenheim SJ et al. Tubulointerstitial renal disease in systemic lupus erythematosus. Arch Intern Med 1985; 145: 1996-1999.
11. Park MH, D'Agati V, Appel GB et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44: 309-319.
12. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71: 491-495.
13. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009; 18: 220-225.
14. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med 2009; 133: 233-248.
15. Austin III HA, Boumaps DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
16. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidey Dis 2000; 35: 904-914.
17. Hiramatsu N, Kuroiwa T, Ikeuchi H et al. Revised classification of lupus nephritis is value in predicting outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford) 2008; 47: 702-707.
18. Hill GS, Delahousse M, Nochy D et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58: 1160-1173.
19. Zappitelli M, Duffy CM, Bernard C et al. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol 2008; 23: 83-91.
20. Singh AK, Ucci A, Madias NE. Predominant tubulointerstitial lupus nephritis. Am J Kidney Dis 1996; 27: 273-278.
21. Fang JT, Chen YC. Systemic lupus erythematosus presenting initially as hydrogen ATPase pump defects of distal renal tubular acidosis. Ren Fail 2000; 22: 647-652.
22. Mori Y, Kishimoto N, Yamahara H et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus nephritis. Clin Exp Nephrol 2005; 9: 79-84.
23. Hayakawa S, Nakabayashi K, Karube M et al. Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus: role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis. Clin Exp Nephrol 2006; 10: 146-151.
24. Omokawa A, Wakui H, Okuyama S et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus erythematosus: phenotype of infiltrating cells. Clin Nephrol 2008; 69: 436-444.
25. Hodgin JB, Whelan J, Markowitz GS et al. Giant cell tubulitis with immune complex deposits in a patient with lupus nephritis. Am J Kidney Dis 2009; 53: 513-517.
26. Yamamoto T, Nagase M, Hishida A et al. Interstitial inflammatory and chronic tubulointerstitial lesions in lupus nephritis: comparison with those in IgA nephropathy. Lupus 1993; 2: 261-268.
27. Schwartz MM, Fennell JS, Lewis EJ. Pathologic changes in the renal tubule in systemic lupus erythematosus. Hum Pathol 1982; 13: 534-547.
28. Alexopoulos E, Seron D, Hartley RB et al. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37: 100-109.
29. Hurtado A, Asato C, Escudero E et al. Clinicopathologic correlations in lupus nephritis in Lima, Peru. Nephron 1999; 83: 323-330.
30. Hill GS, Delahousse M, Nochy D et al. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int 2001; 60: 1893-1903.
31. Zheng L, Sinniah R, Hsu SI. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006; 37: 637-647.
32. Zheng L, Sinniah R, Hsu SI. Pathogenic role of NF-kappaB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem 2008; 56: 517-529.
33. Ferraccioli G, Romano G. Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. Lupus 2008; 17: 533-540.
34. Yung S, Tsang RC, Sun Y et al. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol 2005; 16: 3281-3294.
35. Tan Y, Yu F, Yang H et al. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008; 69: 840-844.
36. Moll S, Menoud PA, French L et al. Tubular up-regulation of clusterin mRNA in murine lupus-like nephritis. Am J Pathol 1998; 152: 953-962.
37. Anders HJ, Banas B, Schlö ndorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854-867.
38. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004; 18: 534-536.
39. Benigni A, Caroli C, Longaretti L et al. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum 2007; 56: 1569-1578.
40. Mittal B, Hurwitz S, Rennke H et al. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004; 44: 1050-1059.
41. Yokoyama H, Wada T, Hara A et al. the Kanazawa Study Group for Renal Diseases and Hypertension. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66: 2382-2388.
42. Hill GS, Delahousse M, Nochy D et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68: 2288-2297.
43. Kim YG, Kim HW, Cho YM et al. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophos-phamide induction treatment. Rheumatology (Oxford) 2008; 47: 311-314.
44. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus nephritis. Nephrol Dial Transplant 2008; 23: 1298-1306.
45. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
46. Yu F, Tan Y, Wu LH et al. Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus 2009; 18: 1073-1081.
47. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
48. Bombardier C, Gladman DD, Hocherg M. Validity and reliability of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
49. Bombardier C, Gladman DD, Urowitz MB et al. The derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
50. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
51. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
52. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
53. Wang HY, Cui TG, Hou FF et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-center observational study. Lupus 2008; 17: 638-644.